164 related articles for article (PubMed ID: 30005153)
1. Novel Interleukin-5 Targeted Treatment Options for Severe Eosinophilic Asthma.
Berendse J; Craig B; Gullickson E
S D Med; 2018 Jun; 71(6):274-276. PubMed ID: 30005153
[No Abstract] [Full Text] [Related]
2. [Severe refractory eosinophilic asthma].
Jäger-Becker D
MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
[No Abstract] [Full Text] [Related]
3. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
4. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
[No Abstract] [Full Text] [Related]
5. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
Han D; Lee JK
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
[No Abstract] [Full Text] [Related]
6. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.
Antonicelli L; Tontini C; Marchionni A; Lucchetti B; Garritani MS; Bilò MB
Allergy; 2020 Feb; 75(2):433-436. PubMed ID: 31166020
[No Abstract] [Full Text] [Related]
7. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
8. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro M; Bacharier LB
Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
[No Abstract] [Full Text] [Related]
9. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Pavord ID; Hanania NA
J Allergy Clin Immunol Pract; 2019; 7(5):1430-1436. PubMed ID: 30962155
[No Abstract] [Full Text] [Related]
10. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
Haldar P; Brightling CE; Singapuri A; Hargadon B; Gupta S; Monteiro W; Bradding P; Green RH; Wardlaw AJ; Ortega H; Pavord ID
J Allergy Clin Immunol; 2014 Mar; 133(3):921-3. PubMed ID: 24418480
[No Abstract] [Full Text] [Related]
11. Anti-interleukin-5 therapy and severe asthma.
Gleich GJ
N Engl J Med; 2009 Jun; 360(24):2577; author reply 2578. PubMed ID: 19522047
[No Abstract] [Full Text] [Related]
12. Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.
Paton DM
Drugs Today (Barc); 2016 Jun; 52(6):323-9. PubMed ID: 27458609
[TBL] [Abstract][Full Text] [Related]
13. The role of interleukin 5 in asthma.
Varricchi G; Canonica GW
Expert Rev Clin Immunol; 2016 Sep; 12(9):903-5. PubMed ID: 27450970
[No Abstract] [Full Text] [Related]
14. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy?
McCallister JW
Am J Respir Crit Care Med; 2011 Nov; 184(10):1096-7. PubMed ID: 22086982
[No Abstract] [Full Text] [Related]
15. Anti-interleukin-5 therapy and severe asthma.
Zarogiannis S; Gourgoulianis KI; Kostikas K
N Engl J Med; 2009 Jun; 360(24):2576; author reply 2577. PubMed ID: 19516040
[No Abstract] [Full Text] [Related]
16. Anti-interleukin-5 therapy and severe asthma.
Szczeklik A
N Engl J Med; 2009 Jun; 360(24):2576-7; author reply 2577. PubMed ID: 19522046
[No Abstract] [Full Text] [Related]
17. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
18. Eosinophils in asthma--closing the loop or opening the door?
Wenzel SE
N Engl J Med; 2009 Mar; 360(10):1026-8. PubMed ID: 19264692
[No Abstract] [Full Text] [Related]
19. [CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma].
Platzer S; Fehr T; Latshang T
Praxis (Bern 1994); 2018; 107(21):1129-1135. PubMed ID: 30326819
[TBL] [Abstract][Full Text] [Related]
20. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]